Lyndra Therapeutics

Gilead Sciences, Inc. (NASDAQ: GILD), which has recently faced a setback with its NASH pipeline and is grappling with an aging HIV franchise, is partnering with a privately held company to develop HIV therapies with the goal of improving medication adherence.  What Happened Lyndra...